证券代码：300138 证券简称：晨光生物 公告编号：2025—048 晨光生物科技集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）2024 年年度权益分 派方案已获 2025 年 5 月 6 日召开的 2024 年年度股东大会审议通过，现将权益分 派事宜公告如下： 一、股东大会审议通过的利润分配方案情况 1、公司 2024 年年度股东大会审议通过的 2024 年年度利润分配方案为：以 公司总股本 483,100,093 股为基数，向全体股东每 10 股派发现金红利 1.30 元（含 税），共计派发现金红利 62,803,012.09 元（含税），剩余未分配利润结转以后 年度。本次分配不以资本公积转增股本、不送红股。利润分配预案公布后至实施 前，如公司总股本由于股权激励行权、可转债转股、股份回购等原因发生变动的， 则按照"分配比例不变"的原则，在利润分配实施公告中披露按公司最新总股本 为基数计算现金分红总额。 2、公司自利润分配方案披露至实施期间公司股本总额未发 ...

北京中银律师事务所 关于晨光生物科技集团股份有限公司 2024 年年度股东大会之 法律意见书 北京 上海 天津 重庆 深圳 三亚 成都 南宁 济南 福州 长沙 银川 南京 赣州 武汉 昆明 杭州 沈阳 西安 合肥 南昌 厦门 鸡西 台州 苏州 青岛 泉州 珠海 地址：北京市朝阳区光华路正大中心北塔 11-12 层 邮编：100020 电话：01065876666 传真：01065876666-6 网址：www.zhongyinlawyer.com 北京中银律师事务所（以下称"本所"）接受晨光生物科技集团股份有限公 司（以下简称"公司"）的委托，根据《中华人民共和国公司法》等法律、法规、 规范性文件及《晨光生物科技集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，就公司 2024 年年度股东大会（以下简称"本次股东大会"）的召 集、召开程序、出席人员及召集人资格、大会表决程序、表决结果等事宜，出具 本法律意见书。本所律师依据相关规定，严格履行了法定职责，遵循了勤勉尽责 和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定的事实真实、 准确、完整，所发表的结论性意见合法、准确，不存在虚假记载 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—047 晨光生物科技集团股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会决议的情况。 一、 会议召开和出席情况 晨光生物科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日 发出了《关于召开 2024 年年度股东大会的通知》，又于 2025 年 4 月 28 日发出 了《关于召开 2024 年年度股东大会的提示性公告》。本次股东大会由董事会召 集，董事长卢庆国先生主持，在公司会议室以现场投票及网络投票相结合的方式 召开。 现场会议召开时间：2025 年 5 月 6 日下午 14:40 现场会议召开地点：河北省邯郸市曲周县城晨光路 1 号公司会议室 二、 议案审议表决情况 经与会股东认真审议，会议采取现场投票和网络投票相结合的方式审议通过 了以下议案： （一）审议通过了《关于<2024 年年度报告全文及摘要>的议案》 表决结果：同意 1 ...

晨光生物科技集团股份有限公司（以下简称"公司"或"晨光生物"）及子 公司——腾冲晨光云麻生物科技有限公司（以下简称"晨光云麻"）于近日正式 取得了八项专利证书，具体情况如下： | 专利名称 | 专利号 | | 证书号 | | | 授权公告日 | | | 类型 | 专利 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | 权人 | | 一种色浆及其制备方法与 | ZL202310586109.7 | 第 | 7904003 | 号 | 2025 | 年 | 04 | 月 | | | | 应用 一种适于工业化生产姜黄 | | | | | 29 2025 | 日 年 | 04 | 月 | | | | 素晶体的方法 | ZL202311688145.0 | 第 | 7904354 | 号 | 29 | 日 | | | | | | 一种从姜黄副产品中回收 | | | | | 2025 | 年 | 04 | 月 | 发明 | | | 姜黄素的方法 | ZL202310951839.2 | 第 ...

Core Viewpoint - The company reported a slight decline in revenue but a significant increase in net profit and earnings per share, indicating strong operational efficiency and profitability despite revenue challenges [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 1.716 billion yuan, a year-on-year decrease of 0.9% [1]. - The net profit attributable to shareholders was 109 million yuan, reflecting a year-on-year increase of 183.7% [1]. - Basic earnings per share (EPS) reached 0.2266 yuan, up 212.6% year-on-year [1]. Business Segment Analysis - The cottonseed business has returned to normal operations, while the plant extraction business has exceeded expectations [2]. - The plant extraction segment generated revenue of 867 million yuan, a year-on-year increase of 13.8%, with a gross margin improvement of 2.15 percentage points [2]. - The cottonseed segment reported revenue of 760 million yuan, a year-on-year decrease of 9.5%, with a gross margin of approximately 6.1% [2]. Market Strategy - The company adopted a strategy of "price for volume," leading to increased sales volume and revenue growth in various product lines [3]. - The price of chili red pigment significantly decreased, resulting in a revenue increase of approximately 7% due to volume elasticity [3]. - The company capitalized on domestic raw material cost advantages to expand into overseas markets, with chili extract sales doubling and contributing to a revenue increase of about 24% [3]. Long-term Outlook - The company is focused on long-term advantages, expanding overseas planting bases, and making breakthroughs in new businesses such as traditional Chinese medicine and health products [3]. - The company anticipates maintaining high growth rates in performance as major products return to a cyclical uptrend [3]. Investment Recommendation - The company is a leading player in the plant extract sector, with stable profitability in key products and a strong growth trajectory in market share [4]. - The ongoing construction of the Zambia plantation is expected to further reduce costs, and the health product business shows significant potential for growth [4]. - Projected EPS for 2025-2027 is 0.67, 0.83, and 1.00 yuan, with corresponding price-to-earnings ratios of 16.3X, 13.1X, and 10.9X, maintaining a "buy" rating [4].

Core Viewpoint - The company reported a mixed performance for Q1 2025, with revenue slightly declining but significant growth in net profit, indicating a potential turning point in profitability driven by improved margins and successful product sales in the plant extraction segment [1][3]. Revenue and Profitability - In Q1 2025, the company achieved revenue of 1.716 billion yuan, a year-on-year decrease of 0.92%, while net profit attributable to shareholders reached 109 million yuan, a year-on-year increase of 183.69% [1]. - The adjusted net profit was 96 million yuan, reflecting a year-on-year increase of 97.83% [1]. Business Segment Performance - The plant extraction business saw multiple products achieving historical sales highs, contributing 867 million yuan in revenue, a year-on-year increase of 13.78%, with a gross profit margin improvement of 2.15 percentage points [1][3]. - The cottonseed business rebounded, generating 760 million yuan in revenue, although this represented a year-on-year decline of 9.49%, but with a significant improvement in gross profit [1][2]. Specific Product Insights - Chili red sales increased by approximately 7% due to a rise in volume despite price adjustments [2]. - Chili extract revenue grew by about 24%, driven by a more than doubling of sales volume [2]. - Lutein sales increased by 50% in the food-grade segment, despite overall market oversupply [2]. - Stevia glycosides saw a revenue increase of approximately 55%, surpassing 80 million yuan, supported by innovative cost advantages [2]. Margin and Cost Management - The company's gross margin improved to 14.16%, and net margin reached 6.38%, with respective year-on-year increases of 5.95 and 4.15 percentage points [3]. - The company maintained strict cost management, with sales, management, financial, and R&D expense ratios showing mixed trends, indicating a focus on efficiency [3]. Future Outlook - The company is expected to continue benefiting from its cost advantages in the plant extraction business and the recovery in the cottonseed market, projecting net profits of 365 million, 457 million, and 564 million yuan for 2025-2027, with respective year-on-year growth rates of 288.51%, 25.18%, and 23.21% [3].

Summary of the Conference Call for Morning Bio (2025 Q1) Company Overview - The conference call pertains to Morning Bio, a company involved in the production and sale of various plant extracts, including chili red, lutein, steviol glycosides, and cottonseed products. Key Points and Arguments Chili Red Sales and Pricing - Chili red sales volume increased by approximately 30% year-on-year in Q1 2025, reaching over 3,000 tons, with an expected annual sales volume between 11,000 to 12,000 tons [2][6] - Current chili red price is at its lowest in nearly a decade, around 120,000 yuan per ton, but the company maintains a reasonable gross margin through cost-plus pricing [2][4][5] - The company anticipates a 10% growth in chili red sales for the year, contingent on raw material cost trends [6] Chili Extract Market Dynamics - Chili extract prices are also at historical lows, with domestic production shifting back to Yunnan due to cost advantages, leading to a more than doubling of sales volume in Q1 [2][7] - The company aims to increase its market share to over 50% through large-scale production and cost reduction strategies [2][8] Lutein Product Performance - Food-grade lutein sales grew by approximately 50% year-on-year, while feed-grade lutein is expected to see minimal growth due to market oversupply [2][9] - The market for lutein is characterized by excess supply, leading to lower prices and potentially reduced profits compared to the previous year [11][12] Steviol Glycosides Growth - Steviol glycosides are experiencing rapid growth primarily due to increased market share, with production efficiency significantly higher than competitors [2][13][15] - The company has optimized its production process, achieving over 95% yield, which contributes to its cost advantage [15] Cottonseed Business Recovery - The cottonseed business turned profitable in Q1 2025, with most cottonseed already procured and market conditions improving [2][16][17] - The company has locked in orders for over 99% of its products, expecting profit realization in Q2 and Q3 to mirror Q1 performance [17][18] Research and Development - R&D expenses in Q1 were at normal levels, focusing on efficiency improvements, new product development, and various health-related sectors [20] Capacity Expansion Plans - The company is expanding its production capacity, including a new health food production line expected to be operational by mid-2025 [21][22] International Market and Trade Impact - Approximately 40% of the company's plant extract business is exported, primarily to Asia, Europe, and South America, with minimal impact from US-China trade tensions due to prior adjustments [24][25] Financial Outlook - The company expects a significant improvement in overall profitability for 2025, with cottonseed business projected to contribute nearly 200 million yuan in incremental revenue [26] - Despite current low prices across products, a reversal in performance is anticipated, with profits expected to gradually improve over the next few years [26] Additional Important Insights - The company is currently at an early turning point in its business cycle, with expectations of gradual recovery in product prices and profitability in the coming years [26]

Investment Rating - The report assigns a positive investment rating, indicating a reversal trend in the company's performance [1]. Core Views - The company achieved a significant increase in net profit in Q1 2025, with a year-on-year growth of 183.69%, while total revenue slightly decreased by 0.92% [1][3]. - The report highlights that the company's plant extraction business showed strong performance, with revenue growth of 13.78%, while the cottonseed business experienced a decline of 9.49% [3]. - The gross profit margin improved to 14.16%, an increase of 5.95 percentage points year-on-year, driven by changes in product mix and lower raw material costs [3]. - The report anticipates a continued recovery in the company's profitability, particularly in the cottonseed business, which is expected to turn profitable [3]. Financial Summary - For Q1 2025, the company reported total revenue of 1.716 billion yuan, with a net profit of 109 million yuan and a non-recurring net profit of 95.92 million yuan [1]. - The projected revenues for 2025-2027 are 6.722 billion yuan, 7.347 billion yuan, and 8.392 billion yuan, respectively, with corresponding net profits of 346 million yuan, 421 million yuan, and 563 million yuan [4]. - The report indicates a significant increase in earnings per share (EPS) from 0.72 yuan in 2025 to 1.17 yuan in 2027, reflecting a positive growth trajectory [4].

证券代码：300138 证券简称：晨光生物 公告编号：2025—044 晨光生物科技集团股份有限公司 关于召开 2024 年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（简称"公司"）于 2025 年 4 月 8 日在巨潮 资讯网（www.cninfo.com.cn）发布了《关于召开 2024 年年度股东大会的通知》 的公告，本次股东大会采取现场投票与网络投票相结合的方式召开。 现将公司 2024 年年度股东大会的有关安排再次提示如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024 年年度股东大会 2、会议召集人：公司董事会，本次股东大会的召开已经公司第五届董事会 第十五次会议审议通过。 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《证券法》 等有关法律法规、规范性文件和《公司章程》相关要求。 4、本次股东大会召开的日期、时间 现场会议召开时间：2025 年 5 月 6 日下午 14:40。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 ...